Nashville, Tennessee (PRWEB) January 20, 2015
DiaTech Oncology, provider of CorrectChemo®, the industry leading functional drug response profiling test that personalizes cancer treatment, has signed a partnership with Cancer Hope in Ra’anana, Israel to offer CorrectChemo to cancer patients in Israel. The CorrectChemo assay identifies, within 72 hours, the most effective chemotherapy drugs in killing cancer cells from a specific patient.
“Cancer is an international problem,” says Robert Henry, president and chief executive officer of DiaTech. “We are pleased to form this partnership with Cancer Hope to extend personalized cancer care to the international community.”
The partnership, finalized on December 9, 2014, now moves to full implementation. Cancer Hope has a successful history of introducing innovative tests that personalize cancer treatment. Currently Cancer Hope includes relationships with 14 medical centers throughout Israel.
“We are thrilled to be a part of DiaTech international expansion and are committed to contributing to the push for personalized cancer care in the healthcare industry in Israel. We strongly believe in the breakthrough CorrectChemo technology”, says Galya Kochav, general manager of Cancer Hope.
“CorrectChemo is the only test on the market that reveals to the treating oncologist the most effective chemotherapy for inducing cell death (apoptosis) in the malignant cells from an individual cancer patient. As our clinical studies show, DiaTech’s CorrectChemo test guides therapy in individual patients, leading to much longer survival times and higher cure rates, and lowers the cost of chemotherapy and cancer care compared to the present standard treatments,” says Cary Presant, M.D., DiaTech chief medical officer.
About DiaTech Oncology
Founded in 2003, DiaTech Oncology (DiaTech) is a privately held international life sciences company based in Nashville Tennessee with laboratories in the United States and Canada. As a certified clinical pathology laboratory DiaTech is focused exclusively on the analysis of live cancer cells and their reaction to individual and combinations of chemotherapy agents to the most effective apoptosis (cell death). DiaTech has the exclusive and perpetual licensing rights for technology developed by researchers at Vanderbilt University as the MiCK® assay, marketed now by DiaTech as Correct Chemo®. The company has seven additional patents filed for improvements made to the CorrectChemo® technology and processes. The company has CLIA and CAP certified laboratories in Franklin, Tennessee and Montreal, Quebec, Canada. For more information visit CorrectChemo.com.
About Cancer Hope
Cancer Hope is a “Personalized Oncology Center” that represents advanced diagnostics for personalized cancer care in Israel. Cancer Hope collaborates with worldwide leaders in cancer diagnostics and medical solutions in order to promote personalized oncology treatment as a standard of care in Israel. Our current diagnostics offering includes: Next Generation Sequencing (NGS) tests offered by the world leading genetic research centers in USA, the CorrectChemo test offered by DiaTech Oncology, and CTC detection and comprehensive analysis offered by European labs. As part of our vision we strive to bring together oncology specialists with cutting-edge diagnostics in order to enable the best care for our patients. For more information visit http://www.cancerhope.co.il